MindMaze Therapeutics Holding (CHIX:MMTXZ) Tariff Resilience Score: 0/10 (As of Jul. 02, 2026)


CHIX:MMTXZ MindMaze Therapeutics Holding SA CHIX:MMTXZ
15 GF Score
Price CHF0.21
! 2 Warning Signs
View Full Analysis

What is MindMaze Therapeutics Holding Tariff Resilience Score?

MindMaze Therapeutics Holding has the Tariff Resilience Score of 0, which implies that the company might have .

MindMaze Therapeutics Holding has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes MindMaze Therapeutics Holding might have .

MindMaze Therapeutics Holding  (CHIX:MMTXz) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

MindMaze Therapeutics Holding Tariff Resilience Score Related Terms

CHIX:MMTXZ
15GF Score
MindMaze Therapeutics Holding SA CHIX:MMTXZ
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MindMaze Therapeutics Holding Business Description

Other Exchanges RLFTY:USAMMTX:Switzerland
Address Avenue de Secheron 15, Geneva, CHE, 1202
MindMaze Therapeutics Holding SA is a Swiss-based, commercial-stage biopharmaceutical and neurotechnology company. The company develops and commercializes digital treatments for neurological diseases and brain disorders. Its technology platform integrates software, sensors, and telehealth, and its solutions are used in clinical and home settings internationally. The company has developed evidence-based, next-generation neurotherapeutics that provide evidence-based motor and cognitive treatments to redefine clinical outcomes in patients with neurological disease and brain disorders. The company also manages Relief's existing portfolio of clinical and commercial biopharmaceutical assets focused on rare dermatological, metabolic, and respiratory diseases.
15GF Score

Get the complete analysis for CHIX:MMTXZ

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF0.21
Price